European stocks waver amid earnings deluge, Iran war deadlock, rate decisions

Brent and WTI topped $100 a barrel as the Iran conflict and a U.S.-Iran impasse kept the Strait of Hormuz effectively blocked, raising the risk of a broader energy shock. European equities were broadly lower, while investors also focused on a likely unchanged Fed rate decision later in the day. Company earnings were mixed: Adidas rose more than 7%, UBS jumped on an 80% profit increase, and STMicroelectronics and Airbus gained, while GSK fell over 3% and Aena weakened.

Analysis

The market is treating this as a classic oil shock, but the more interesting edge is that the first-round winners are not the obvious energy names—they're the balance-sheet-sensitive financials and industrials with pricing power and USD-linked revenue. For UBS and Santander, higher volatility and higher-for-longer rates can support trading income and net interest margins in the near term, while the real risk is a delayed credit-quality turn over the next 2-4 quarters if energy spikes start hitting European consumer and SME balance sheets. That makes bank beta attractive only as a tactical trade, not a medium-term compounder here.

STM looks like the cleanest semiconductor beneficiary because the market is still underestimating how much of its earnings base is tied to auto and industrial end-demand rather than pure AI. If oil stays elevated, the second-order effect is a slower European auto production cycle and weaker discretionary spending, which can offset the valuation support from “inflation hedge” narratives. In other words, STM can work on a short squeeze basis, but the fundamental impulse is less durable than the price action suggests.

GSK’s weakness is a signal that defensives are no longer being paid for safety when inflation expectations are re-accelerating and the Fed is unlikely to cut into an energy shock. That creates a relative-value setup: duration-sensitive defensives and rate proxies can underperform even if earnings are stable, because the market will demand a higher discount rate for lower-growth cash flows. The biggest tail risk is not just oil at a higher level, but oil staying high long enough to reprice central-bank reaction functions and compress equity multiples across Europe.

Consensus is probably overestimating how quickly geopolitical supply can normalize and underestimating how fast the macro transmission hits via rates, FX, and consumer demand. The move is still early enough that momentum can continue for days, but over a multi-month horizon the better expression is to own inflation beneficiaries and fade expensive defensives and rate-sensitive cyclicals. If tanker flow remains constrained for another 2-3 weeks, expect a broader earnings reset across European consumer and transport names, not just energy.

Key Decisions for Investors

• Trade UBS long versus GSK short for 2-6 weeks: UBS should retain volatility and trading-income tailwinds, while GSK is vulnerable to rising discount rates and defensive-factor de-rating. Risk/reward favors the pair if oil stays elevated and the Fed stays on hold.
• Buy STM on pullbacks for a tactical 1-3 week trade, but use a tight stop: the name benefits from the current risk-on-for-earnings reflex, yet auto/industrial demand can soften if energy prices persist. Aim for momentum continuation, not a full fundamental re-rating.
• Initiate a short in European consumer discretionary baskets against energy exposure over the next 1-2 months: inflation pass-through and margin pressure will likely show up before earnings revisions do. This is a cleaner macro hedge than shorting broad indices outright.
• Use SAN as a trade, not a core long: buy only if you want a 1-2 month carry/volatility expression, because higher rates help NII before credit costs catch up. If oil remains above current levels for several weeks, tighten risk quickly.
• Avoid adding to defensives like GSK until the market fully prices a higher-for-longer rate path; if you need exposure, prefer option structures over cash equity to limit downside from de-rating.